Predictive Factors of Eczematous Eruptions and Candidiasis during anti IL-17 Treatment in Psoriatic Patients: a Multicenter Italian Real-life Experience in Lazio Region.
Giacomo Caldarola, Eleonora De Luca, Simone Amato, Alfredo Belcastro, Nicoletta Bernardini, Luca Bianchi, Annunziata Dattola, Clara De Simone, Gaia Moretta, Sabatino Pallotta, Ketty Peris, Antonio Richetta, Raimondo Rossi, Nevena Skroza, Marco Galluzzo
{"title":"Predictive Factors of Eczematous Eruptions and Candidiasis during anti IL-17 Treatment in Psoriatic Patients: a Multicenter Italian Real-life Experience in Lazio Region.","authors":"Giacomo Caldarola, Eleonora De Luca, Simone Amato, Alfredo Belcastro, Nicoletta Bernardini, Luca Bianchi, Annunziata Dattola, Clara De Simone, Gaia Moretta, Sabatino Pallotta, Ketty Peris, Antonio Richetta, Raimondo Rossi, Nevena Skroza, Marco Galluzzo","doi":"10.1093/ced/llaf271","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anti-interleukin (IL)-17 therapies have revolutionized psoriasis treatment, offering excellent clinical outcomes and safety profiles. However, these drugs have been associated with class-specific side effects, Candida infections and eczematous reactions.</p><p><strong>Objective: </strong>To assess the frequency of Candida infections and cutaneous eczematous eruptions in patients with plaque psoriasis treated with secukinumab, ixekizumab, brodalumab, or bimekizumab and to identify risk factors.</p><p><strong>Methods: </strong>A multicenter, retrospective, observational study was conducted involving patients with plaque psoriasis treated with anti-IL-17 biologics at five outpatient clinics in Lazio, Italy. Demographic, clinical data, treatment characteristics, and adverse events were analyzed. Cox regression models were used to identify factors associated with the occurrence of these adverse events.</p><p><strong>Results: </strong>Among 1075 patients, 34 (3.2%) developed eczema, and 36 (3.3%) had candidiasisTherapy was discontinued in 78.1% of eczema cases and 50% of candidiasis cases. Multivariate analysis showed that ixekizumab (HR 3.45, p = 0.050) and atopic history (HR 5.43, p = 0.023) were correlated with eczema, while bimekizumab (HR 23.30, p = 0.002) was strongly associated with candidiasis.</p><p><strong>Conclusions: </strong>Anti-IL-17 therapies show varying risks of eczema and candidiasis. Personalized strategies, regular monitoring, and prophylactic measures are essential to improve outcomes.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf271","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Anti-interleukin (IL)-17 therapies have revolutionized psoriasis treatment, offering excellent clinical outcomes and safety profiles. However, these drugs have been associated with class-specific side effects, Candida infections and eczematous reactions.
Objective: To assess the frequency of Candida infections and cutaneous eczematous eruptions in patients with plaque psoriasis treated with secukinumab, ixekizumab, brodalumab, or bimekizumab and to identify risk factors.
Methods: A multicenter, retrospective, observational study was conducted involving patients with plaque psoriasis treated with anti-IL-17 biologics at five outpatient clinics in Lazio, Italy. Demographic, clinical data, treatment characteristics, and adverse events were analyzed. Cox regression models were used to identify factors associated with the occurrence of these adverse events.
Results: Among 1075 patients, 34 (3.2%) developed eczema, and 36 (3.3%) had candidiasisTherapy was discontinued in 78.1% of eczema cases and 50% of candidiasis cases. Multivariate analysis showed that ixekizumab (HR 3.45, p = 0.050) and atopic history (HR 5.43, p = 0.023) were correlated with eczema, while bimekizumab (HR 23.30, p = 0.002) was strongly associated with candidiasis.
Conclusions: Anti-IL-17 therapies show varying risks of eczema and candidiasis. Personalized strategies, regular monitoring, and prophylactic measures are essential to improve outcomes.
背景：抗白细胞介素(IL)-17疗法已经彻底改变了银屑病的治疗，提供了良好的临床结果和安全性。然而，这些药物与特定类别的副作用，念珠菌感染和湿疹反应有关。目的：评估使用secukinumab、ixekizumab、brodalumab或bimekizumab治疗的斑块型银屑病患者念珠菌感染和皮肤湿疹爆发的频率，并确定危险因素。方法：一项多中心、回顾性、观察性研究在意大利拉齐奥的5个门诊诊所对斑块型银屑病患者进行了抗il -17生物制剂治疗。分析了人口统计学、临床资料、治疗特点和不良事件。使用Cox回归模型来确定与这些不良事件发生相关的因素。结果：1075例患者中，34例（3.2%）发生湿疹，36例（3.3%）发生念珠菌病。78.1%的湿疹患者和50%的念珠菌病患者停止治疗。多因素分析显示，伊谢珠单抗（HR 3.45, p = 0.050）和特应性史（HR 5.43, p = 0.023）与湿疹相关，而比美珠单抗（HR 23.30, p = 0.002）与念珠菌病密切相关。结论：抗il -17治疗对湿疹和念珠菌病有不同的风险。个性化策略、定期监测和预防措施对于改善结果至关重要。
期刊介绍：
Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
